ProgrammableMarketing/itftherapeutics.com (opens in a new tab)
PDF

Views

  • Plan
  • Roadmap
  • Research

On this page

  • The brief
  • Start here
  • Idea portfolio
  • Effort vs impact
  • This week · 6
  • This quarter · 9
  • Big bets · 3
  • Wildcards · 3
Generated Oct 26, 2026
  1. Programmable
  2. Playbooks
  3. ITF Therapeutics
ITF Therapeutics logo

growth playbook · Oct 26, 2026

itftherapeutics.com (opens in a new tab)

ITF Therapeutics growth playbook

Diagnosis

ITF Therapeutics brought DUVYZAT to U.S. families quickly and backs it with strong patient support (ITF ARC), real patient stories, community letters in English and Spanish, and steady data presentations.

Its hiring shows the next phase: new patient and HCP marketing directors, a bigger field team in seven territories, MLR operations, access and analytics leaders, and a second therapeutic area in Phase III.

The gaps are in the digital path around those hires: the Spanish brand page sends families to English forms and never mentions ARC, the brand sitemap is a year old, event dates are invisible to search, and corporate pages have no descriptions. This playbook fixes those first, then builds persistence support, fast rep routing, access-stall alerts, an ambassador program and one shared funnel, and bets on evidence communication, readiness for a second area and earlier diagnosis.

Growth Score

7/10

Biggest Opportunity

Reach every family in their own language and keep them on therapy with the support ITF already offers, while the new field and marketing teams make each HCP request count.

Biggest Risk

Competing Duchenne therapies with Spanish sites and established awareness, plus review queues that slow two new marketing teams at once.

01

Start here

The three moves to make first. Each one is written up in full below.

  1. 1

    Finish the Spanish DUVYZAT path: a Spanish sign-up form, Spanish stories and ITF ARC in Spanish on duvyzat.com/es/

    List every English link on /es/ and the Spanish assets that already exist.

    High impact First result in 6 weeks
  2. 2

    Rebuild the duvyzat.com sitemap so search engines find the long-term data and Stories of Strength pages

    Export the live page list and compare it with the sitemap.

    Medium impact First result in 2 weeks
  3. 3

    Write meta descriptions for itftherapeutics.com, starting with the homepage, product and patient pages

    Write the homepage description.

    Medium impact First result in 3 weeks

02

Your idea portfolio

21 ideas, grouped by when to run them. Open any idea for how to run it: the steps, who to approach, copy you can use, and how to measure it.

  • 8 ideas are marked Unexpected: plays you are unlikely to have tried.

Every idea placed by the effort it takes against the impact it could have. Quick wins sit top left; select a number to open that idea. The filters below narrow the list by status, timing, category and what Programmable can build.

Effort vs impactEach number is an idea. Select one to open it.
Impact →
Quick wins · 0Big bets · 12Fill-ins · 7Reconsider · 2
Effort →

Showing 21 of 21 ideas

This week 6

Quick wins with a clear first action.

  • 01

    ITF already invests in Spanish: every community letter now has a Spanish version and the ARC brochure exists in Spanish. But duvyzat.com/es/ is one page, and its main buttons lead Spanish-speaking families into English: "MANTENERSE INFORMADO" opens the English sign-up form, "HISTORIAS REALES" opens the English stories page, and the page never mentions ITF ARC, the support program that offers translation, copay help and in-home lab monitoring. AGAMREE and ELEVIDYS both run Spanish versions.

    High impactMedium effort First result in 6 weeks Director

    First action

    List every English link on /es/ and the Spanish assets that already exist.

    How to measure it

    Monthly sign-ups from /es/

    Now
    –
    Target
    Baseline, then +50%
    By
    90 days

    Steps

    1. 1

      Inventory

      English links on /es/ and existing Spanish assets (letters, brochures, PDFs).

      Director, Duvyzat Patient Marketing 2 days

    2. 2

      Translate the form

      Spanish sign-up with a language field and the same consent wording.

      Director, Duvyzat Patient Marketing 1 week

    3. 3

      Add ITF ARC

      A Spanish ARC section with the Spanish brochure and phone line.

      Director, Duvyzat Patient Marketing 1 week

    4. 4

      Subtitle the videos

      Spanish subtitles for the Real Stories videos.

      Director, Duvyzat Patient Marketing 2 weeks

    5. 5

      MLR review

      Route all translations as one submission.

      Director, MLR Operations 2 weeks

    6. 6

      Route follow-up

      Spanish sign-ups flagged to ARC and the field team.

      Patient services hub lead 1 week

    7. 7

      Measure

      Spanish sign-ups, ARC calls and starts from Spanish-speaking families.

      Sr. Manager, Field Reporting & Analytics monthly

    First result
    6 weeks
    Cost
    Translation, subtitling and review time
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Translate the sign-up form first and point the Spanish button at it.

    Why it works

    Give the Spanish page its own path: a Spanish sign-up form (with a language field that also goes into the hub record), Spanish subtitles for the Real Stories videos, a Spanish ITF ARC section linking the existing Spanish brochure and the ARC phone line, and a Spanish advocacy-group list. Update the ™ to ® while it is in review. Then tag Spanish sign-ups so ARC and the field team can follow up in Spanish.

    The content is already approved in English and partly translated, so this is mostly MLR review of translations, and it removes the point where a Spanish-speaking caregiver drops out: the form.

    Ready to use

    ChecklistSpanish path launch list

    [ ] Spanish sign-up form with a language field
    [ ] "MANTENERSE INFORMADO" points to the Spanish form
    [ ] Spanish ITF ARC section and brochure link
    [ ] Spanish subtitles on the Real Stories videos
    [ ] Spanish advocacy-group list
    [ ] DUVYZAT(R) mark updated
    [ ] Spanish sign-ups tagged for ARC follow-up
    [ ] One MLR submission for all translations

    Risks and how to handle them

    • Translation errors in medical wording

      Use certified medical translators and MLR review.

    • Follow-up capacity in Spanish

      Confirm ARC translation services before launch.

    Evidence

    • Brand websiteduvyzat.com/es/ is a single Spanish page whose menu items jump to sections of that page. Its "MANTENERSE INFORMADO" button opens the English sign-up form at /stay-informed/ (an English-language page), "HISTORIAS REALES" opens the English /real-stories/ page and the advocacy-group links open an English page. The Spanish page does not mention ITF ARC at all and still shows the old "DUVYZAT™" mark, while the English pages use "DUVYZAT®" (checked twice on October 23, 2026).Source
    • Brand websiteITF ARC page: insurance navigation, prior authorization and appeal support, home delivery, "Personalized pharmacist guidance", "Translation services available as needed", in-home lab monitoring with a registered nurse, a copay program ("as little as $0 per month" for eligible commercially insured patients), a Patient Assistance Program and temporary supply programs. English and Spanish ARC brochures are linked from this English page only.Source
    • Your websiteCommunity Letters: six letters from March 2024 to March 2026, each with a Spanish version (the Spanish versions were added on September 10, 2026), and a Spanish press release on U.S. commercial availability.Source
    • Brand websitePatient sign-up form: first and last name, email, ZIP code, patient or caregiver or other, and "Currently on treatment with DUVYZAT? Yes / No", with consent to marketing and market research; there is no language choice.Source
    • Competitor researchRivals' own sites: AGAMREE (vamorolone), "an FDA-approved corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older", links a Spanish site at /es/; the ELEVIDYS site declares a Spanish ("es") version; EMFLAZA (deflazacort): "Help extend his now with EMFLAZA".Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
  • 02

    The duvyzat.com sitemap was generated with Screaming Frog with every page dated August 2025. It lists a safety page that now returns 404 and several old addresses that redirect, while the newer long-term data, key safety information and Stories of Strength pages are missing.

    Medium impactLow effort First result in 2 weeks Director

    First action

    Export the live page list and compare it with the sitemap.

    How to measure it

    Indexed share of live pages

    Now
    –
    Target
    100%
    By
    30 days

    Steps

    1. 1

      Crawl

      List live pages and their status.

      Web agency 1 day

    2. 2

      Rebuild

      Only live, final addresses.

      Web agency 1 day

    3. 3

      Fix the 404

      Redirect the old safety page to key safety information.

      Web agency 1 hour

    4. 4

      Submit

      Search Console for both domains.

      Web agency 1 hour

    5. 5

      Add to releases

      Sitemap check in the release list.

      Director, Duvyzat Patient Marketing 1 hour

    6. 6

      Monitor

      Coverage report monthly.

      Web agency monthly

    First result
    2 weeks
    Cost
    Agency hours
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Redirect the 404 safety page today.

    Why it works

    Regenerate the sitemap from the live site, remove the 404 and redirected addresses, add the current pages and Spanish PDFs, submit it in Search Console, and make it part of every site release checklist.

    Families search for "Duchenne treatment" and "givinostat"; pages missing from the sitemap are found later, and a 404 safety page is a poor first visit.

    Risks and how to handle them

    • Redirect needs review

      Treat the redirect as a technical change and log it with MLR.

    Evidence

    • Brand websiteduvyzat.com sitemap (Screaming Frog, every page dated August 4, 2025): 23 URLs; /taking-duvyzat/safety-information/ returns 404 (checked twice), several entries redirect, and current pages such as /results-with-duvyzat/long-term-data/, /results-with-duvyzat/key-safety-information/ and /real-stories/stories-of-strength/ are not listed.Source
    • Brand websiteStories of Strength: four families living with Duchenne share their experience with DUVYZAT, with healthcare providers, at events with a "REGISTER NOW" button; the event list loads in the browser, so the plain page shows no dates or places. The Real Stories page carries five patient videos, and the site footer links a DUVYZAT YouTube channel.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
  • 03

    The corporate homepage and the other pages checked have no meta description, so search results and link previews show whatever text Google picks. Real visitors already get a fast site (it passes Core Web Vitals), so the gap is how the pages are described.

    Medium impactLow effort First result in 3 weeks Head of Corporate Communicati…

    First action

    Write the homepage description.

    How to measure it

    Search click-through

    Now
    –
    Target
    +15%
    By
    60 days

    Steps

    1. 1

      List pages

      Top 20 by traffic.

      Head of Corporate Communications 1 hour

    2. 2

      Draft

      One line each, approved wording.

      Head of Corporate Communications 1 day

    3. 3

      Review

      MLR for product pages.

      Director, MLR Operations 1 week

    4. 4

      Publish

      Yoast fields.

      Web agency 2 hours

    5. 5

      Fix link text

      Replace "Learn more" with descriptive text.

      Web agency 1 day

    6. 6

      Measure

      Search Console click-through.

      Head of Corporate Communications monthly

    First result
    3 weeks
    Cost
    $0 plus review time
    Owner
    Head of Corporate Communications

    Smallest test

    Publish the homepage description this week.

    Why it works

    Write one-line descriptions for the 20 main pages (homepage, product, pipeline, patient advocacy, sponsorships, community letters, careers) in Yoast, using approved language, and give links descriptive text.

    Clear descriptions lift clicks from search and give AI assistants an accurate summary of who ITF is.

    Risks and how to handle them

    • Product wording in descriptions

      Keep product pages to approved text.

    Evidence

    • Google PageSpeeditftherapeutics.com homepage: Lighthouse mobile performance 73 (desktop 89) with a lab Largest Contentful Paint of 6.4 seconds on mobile, but real Chrome visitors pass Core Web Vitals (LCP 1.7 seconds at the 75th percentile, INP 49 ms, CLS 0). SEO 85 ("Document does not have a meta description", "Links do not have descriptive text"); accessibility 92 with low colour contrast and small touch targets flagged.Source
    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
  • 04

    The sign-up form already asks "Currently on treatment with DUVYZAT?", and the new Patient Marketing Director is measured on "adoption, compliance and persistence". Families who answer yes are the ones a persistence program should reach first.

    High impactMedium effort First result in 6 weeks Director

    First action

    Count sign-ups who answered yes in the last 90 days.

    How to measure it

    Families still on therapy at 6 months

    Now
    –
    Target
    +5 points
    By
    2 quarters

    Steps

    1. 1

      Segment

      Yes and no answers in the CRM.

      Director, Duvyzat Patient Marketing 2 days

    2. 2

      Write the series

      Four approved emails per segment.

      Director, Duvyzat Patient Marketing 2 weeks

    3. 3

      Review

      MLR submission.

      Director, MLR Operations 2 weeks

    4. 4

      Link to ARC

      Every email offers the ARC phone line.

      Patient services hub lead 1 day

    5. 5

      Launch

      Triggered on sign-up.

      Director, Duvyzat Patient Marketing 1 week

    6. 6

      Measure

      Opens, ARC calls, persistence.

      Sr. Director, Integrated Performance Insights & Forecasting monthly

    First result
    6 weeks
    Cost
    Email platform and review time
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Send one ARC email to families who answered yes.

    Why it works

    Split sign-ups by that answer. Families on treatment get a short, approved series: what ITF ARC offers, the blood tests the doctor will order, how in-home lab monitoring works, and caregiver stories; families not yet on treatment get disease education and ARC information. Hand questions to ARC and medical information.

    The answer is already collected, and timely support in the first months is when families most often stop.

    Risks and how to handle them

    • Medical questions by email

      Route to medical information, never answer in marketing.

    Evidence

    • Brand websitePatient sign-up form: first and last name, email, ZIP code, patient or caregiver or other, and "Currently on treatment with DUVYZAT? Yes / No", with consent to marketing and market research; there is no language choice.Source
    • Brand websiteITF ARC page: insurance navigation, prior authorization and appeal support, home delivery, "Personalized pharmacist guidance", "Translation services available as needed", in-home lab monitoring with a registered nurse, a copay program ("as little as $0 per month" for eligible commercially insured patients), a Patient Assistance Program and temporary supply programs. English and Spanish ARC brochures are linked from this English page only.Source
    • Brand websiteduvyzat.com homepage: "The only nonsteroidal treatment indicated for Duchenne muscular dystrophy in people 6 years of age and older, regardless of their genetic variant or ability to walk." The Important Safety Information tells patients the doctor will check blood counts and triglyceride levels before and during treatment.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
  • 05

    ITF is hiring a Patient Marketing Director and an HCP Marketing Director at the same time as a Director of MLR Operations who will track cycle time and review rounds in Veeva Vault PromoMats. Two new teams writing at once is the moment review queues grow.

    High impactMedium effort First result in 1 quarter Director

    First action

    List the claims used in the last ten approved pieces.

    How to measure it

    Median review cycle

    Now
    –
    Target
    -30%
    By
    2 quarters

    Steps

    1. 1

      Collect claims

      From approved materials.

      Director, MLR Operations 2 weeks

    2. 2

      Tag modules

      Claims, safety, images, Spanish.

      Director, MLR Operations 2 weeks

    3. 3

      Set rules

      Allowed combinations.

      Director, MLR Operations 1 week

    4. 4

      Train teams

      Marketers and agencies.

      Director, MLR Operations 1 day

    5. 5

      Pilot

      Five emails built from modules.

      Director, Duvyzat Patient Marketing 2 weeks

    6. 6

      Track

      Cycle time and rounds.

      Director, MLR Operations monthly

    First result
    1 quarter
    Cost
    PromoMats configuration time
    Owner
    Director, MLR Operations

    Smallest test

    Build modules for the five most used claims.

    Why it works

    Create a library of approved claims, safety statements, images and Spanish equivalents as reusable modules in PromoMats, with rules for which modules can be combined. New emails, social posts and slides are then built from approved parts and reviewed faster.

    Faster review means more tests and fresher content for both directors, without lowering the bar.

    Risks and how to handle them

    • Modules used out of context

      Final review still checks every piece.

    Evidence

    • HiringDirector, Medical, Legal, & Regulatory (MLR) Operations (posted October 2, 2026): owns the review model "end-to-end", is business owner for "Veeva Vault PromoMats", plans "reviewer capacity" for "new product launches, indications, label changes", and tracks "submission volume, cycle time, SLA adherence, review rounds".Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
    • HiringDirector, Duvyzat HCP Marketing (posted October 14, 2026): owns "the HCP commercial strategy, omnichannel engagement, customer insights, congress strategy and agency leadership", will "Establish KPIs, dashboards and ROI measurement", lead "strategic congress planning, advisory boards" and "HCP product public relations", and "navigate all MLR requirements".Source
    • Brand websiteduvyzat.com/es/ is a single Spanish page whose menu items jump to sections of that page. Its "MANTENERSE INFORMADO" button opens the English sign-up form at /stay-informed/ (an English-language page), "HISTORIAS REALES" opens the English /real-stories/ page and the advocacy-group links open an English page. The Spanish page does not mention ITF ARC at all and still shows the old "DUVYZAT™" mark, while the English pages use "DUVYZAT®" (checked twice on October 23, 2026).Source
  • 06

    Stories of Strength events let families hear from others living with Duchenne, but the event list loads only in the browser, so search engines, AI assistants and partner calendars see no dates or places.

    Medium impactLow effort First result in 1 month Director

    First action

    Check which upcoming events are in the CMS.

    How to measure it

    Registrations per event

    Now
    –
    Target
    +30%
    By
    90 days

    Steps

    1. 1

      List events

      Next two quarters.

      Director, Duvyzat Patient Marketing 1 day

    2. 2

      Render in HTML

      Server-side list with structured data.

      Web agency 1 week

    3. 3

      Add to corporate site

      Upcoming events block.

      Head of Corporate Communications 2 days

    4. 4

      Share with partners

      Community calendars.

      Patient Advocacy lead 1 week

    5. 5

      Review

      Event listings through MLR.

      Director, MLR Operations 1 week

    6. 6

      Measure

      Registrations by source.

      Director, Duvyzat Patient Marketing monthly

    First result
    1 month
    Cost
    Agency hours
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    List the next event in plain text on the page.

    Why it works

    Render each event (date, city or online, speaker family, registration link) in the page HTML with event structured data, list upcoming events on itftherapeutics.com, and send dates to partner organisations' community calendars.

    Families look for local events; visible dates reach them through search and through the groups they already trust.

    Risks and how to handle them

    • Partner compliance rules

      Share only approved event descriptions.

    Evidence

    • Brand websiteStories of Strength: four families living with Duchenne share their experience with DUVYZAT, with healthcare providers, at events with a "REGISTER NOW" button; the event list loads in the browser, so the plain page shows no dates or places. The Real Stories page carries five patient videos, and the site footer links a DUVYZAT YouTube channel.Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source

This quarter 9

The core plays for the next three months.

  • 07

    duvyzathcp.com has a Request a Rep form and an NPI-based sign-up, and ITF is filling seven Key Account Manager territories. A neurologist who asks for a visit is the warmest HCP lead there is.

    High impactMedium effort First result in 1 month Director

    First action

    Measure today's time from rep request to first contact.

    How to measure it

    Requests answered in 1 business day

    Now
    –
    Target
    90%
    By
    60 days

    Steps

    1. 1

      Map territories

      NPI and ZIP to KAM.

      Commercial operations 1 week

    2. 2

      Set routing

      CRM alerts to KAM and RBD.

      Commercial operations 1 week

    3. 3

      Write follow-up

      Approved email.

      Director, Duvyzat HCP Marketing 2 weeks

    4. 4

      Train KAMs

      Response standard.

      Head of Sales 1 day

    5. 5

      Report

      Dashboard by territory.

      Sr. Manager, Field Reporting & Analytics weekly

    6. 6

      Review

      Lead-to-prescriber conversion.

      Director, Duvyzat HCP Marketing monthly

    First result
    1 month
    Cost
    CRM configuration
    Owner
    Director, Duvyzat HCP Marketing

    Smallest test

    Route one week of requests by hand and time the response.

    Why it works

    Map NPI and ZIP to territory, send each request to the KAM and Regional Business Director with a one-business-day target, add an approved follow-up email, and report requests, response time and first prescriptions by territory on the HCP dashboard.

    Speed matters when a clinician is considering a new therapy for a patient, and the new territories need a steady flow of named leads.

    Risks and how to handle them

    • Vacant territories

      Route to the Regional Business Director until filled.

    Evidence

    • HCP websiteduvyzathcp.com has a "REQUEST A REP" form "for US healthcare providers only", an NPI-based "Sign up for updates" form with consent to contact by email, text and phone, a video library, resources and a Patient Start Form.Source
    • HiringField build-out: a Head of Sales (posted August 24, 2026) to lead "Regional Business Directors and Key Account Managers" for "DUVYZAT (givinostat), the first nonsteroidal therapy approved for all genetic variants of Duchenne muscular dystrophy", set objectives for "patient starts, patient adherence", and build relationships with "neuromuscular centers, MDA care centers, academic and pediatric institutions"; seven Key Account Manager posts (Boston, Detroit, Miami, Minneapolis, New York City, Philadelphia, San Antonio) and a Regional Business Director, Central.Source
    • HiringDirector, Duvyzat HCP Marketing (posted October 14, 2026): owns "the HCP commercial strategy, omnichannel engagement, customer insights, congress strategy and agency leadership", will "Establish KPIs, dashboards and ROI measurement", lead "strategic congress planning, advisory boards" and "HCP product public relations", and "navigate all MLR requirements".Source
  • 08

    The Field Reimbursement Manager is hired to find "specific patients that are not moving forward due to insurance delays" with the hub and specialty pharmacy, and the Head of Value & Access has written publicly about "FDA Approval Granted, Access Denied". ITF ARC already offers prior authorization and appeal support and temporary supply.

    High impactMedium effort First result in 1 quarter Field Reimbursement Manager

    First action

    Pull the current list of pending enrolments by days waiting.

    How to measure it

    Median days to first shipment

    Now
    –
    Target
    -25%
    By
    2 quarters

    Steps

    1. 1

      Define stall

      Days and reasons.

      Field Reimbursement Manager 1 week

    2. 2

      Build report

      Weekly hub feed.

      Patient services hub lead 2 weeks

    3. 3

      Privacy check

      What can be shared with the field.

      Compliance 1 week

    4. 4

      Toolkit

      Checklists and templates.

      Field Reimbursement Manager 1 month

    5. 5

      Review

      MLR for the toolkit.

      Director, MLR Operations 2 weeks

    6. 6

      Measure

      Days to shipment by region.

      Sr. Director, Integrated Performance Insights & Forecasting monthly

    First result
    1 quarter
    Cost
    Hub reporting time
    Owner
    Field Reimbursement Manager

    Smallest test

    Review the ten longest-waiting enrolments with the hub.

    Why it works

    Set a weekly hub report of enrolments stuck beyond a set number of days, with the reason, and send it (within privacy rules) to the FRM and KAM. Publish an office-staff toolkit on duvyzathcp.com: prior authorization checklist, appeal letter template, temporary supply steps and ARC contacts.

    Every week saved in access is a patient who starts sooner and a prescriber who prescribes again.

    Risks and how to handle them

    • Patient privacy

      Share only what compliance approves.

    Evidence

    • HiringAccess and thought leaders: a Field Reimbursement Manager (Texas, Missouri, Illinois, Michigan, Wisconsin, Minnesota) will "Partner with the sales team and patient hub/SP to identify both accounts that are experiencing reimbursement issues and specific patients that are not moving forward due to insurance delays"; a Thought Leader Liaison (East) is "the field-based arm of Marketing" for the "top 10-15 percent of KOLs".Source
    • Brand websiteITF ARC page: insurance navigation, prior authorization and appeal support, home delivery, "Personalized pharmacist guidance", "Translation services available as needed", in-home lab monitoring with a registered nurse, a copay program ("as little as $0 per month" for eligible commercially insured patients), a Patient Assistance Program and temporary supply programs. English and Spanish ARC brochures are linked from this English page only.Source
    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
    • HCP websiteduvyzathcp.com has a "REQUEST A REP" form "for US healthcare providers only", an NPI-based "Sign up for updates" form with consent to contact by email, text and phone, a video library, resources and a Patient Start Form.Source
  • 09

    The Patient Marketing Director will "Lead and develop the patient ambassador program", and Stories of Strength already has four families who speak about their experience. Families trust other families most.

    High impactMedium effort First result in 1 quarter Director

    First action

    Write the ambassador agreement and training outline.

    How to measure it

    Attendees per quarter

    Now
    –
    Target
    300
    By
    2 quarters

    Steps

    1. 1

      Policy

      Consent, fees, reporting.

      Compliance 2 weeks

    2. 2

      Training

      Approved messages and safety.

      Director, Duvyzat Patient Marketing 1 month

    3. 3

      Recruit

      Families from new regions.

      Patient Advocacy lead 1 quarter

    4. 4

      Plan events

      Near care centers.

      Director, Duvyzat Patient Marketing 1 month

    5. 5

      Run

      Regional and online events.

      Director, Duvyzat Patient Marketing monthly

    6. 6

      Measure

      Attendance and sign-ups.

      Director, Duvyzat Patient Marketing monthly

    First result
    1 quarter
    Cost
    Speaker fees and events
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Run one regional event with an existing speaker family.

    Why it works

    Formalise the program: consent, training on approved messages and adverse-event reporting, a speaker fee policy, and a calendar of regional events near the centers the field team covers. Add new families over time from different regions and languages, including Spanish.

    Peer stories answer the questions families do not ask a doctor, and regional events put them where families already gather.

    Risks and how to handle them

    • Ambassador fatigue

      Limit events per family and rotate.

    Evidence

    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
    • Brand websiteStories of Strength: four families living with Duchenne share their experience with DUVYZAT, with healthcare providers, at events with a "REGISTER NOW" button; the event list loads in the browser, so the plain page shows no dates or places. The Real Stories page carries five patient videos, and the site footer links a DUVYZAT YouTube channel.Source
    • HiringField build-out: a Head of Sales (posted August 24, 2026) to lead "Regional Business Directors and Key Account Managers" for "DUVYZAT (givinostat), the first nonsteroidal therapy approved for all genetic variants of Duchenne muscular dystrophy", set objectives for "patient starts, patient adherence", and build relationships with "neuromuscular centers, MDA care centers, academic and pediatric institutions"; seven Key Account Manager posts (Boston, Detroit, Miami, Minneapolis, New York City, Philadelphia, San Antonio) and a Regional Business Director, Central.Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
  • 10

    ITF presented givinostat data at the 2025 Neuromuscular Study Group meeting and the 2025 and 2026 MDA Clinical and Scientific Conferences, and the HCP Marketing Director will lead congress strategy and advisory boards.

    High impactMedium effort First result in 1 quarter Director

    First action

    List the next three congresses and the target HCPs attending.

    How to measure it

    HCP meetings per congress

    Now
    –
    Target
    +30%
    By
    2 quarters

    Steps

    1. 1

      Calendar

      Next 12 months.

      Director, Duvyzat HCP Marketing 1 week

    2. 2

      Invite

      Approved pre-congress email.

      Director, Duvyzat HCP Marketing 2 weeks

    3. 3

      KOL plan

      TLL meetings.

      Thought Leader Liaison 2 weeks

    4. 4

      Booth

      Approved materials.

      Director, Duvyzat HCP Marketing 1 month

    5. 5

      Follow up

      KAMs within a week.

      Head of Sales 1 week

    6. 6

      Measure

      Meetings and new prescribers.

      Sr. Manager, Field Reporting & Analytics per congress

    First result
    1 quarter
    Cost
    Congress budget
    Owner
    Director, Duvyzat HCP Marketing

    Smallest test

    Plan follow-up for the next congress.

    Why it works

    For each congress, plan before (approved invitations to target HCPs by NPI), during (booth, KOL meetings with the Thought Leader Liaison, medical presentations kept separate) and after (follow-up by KAMs within a week). Measure meetings, rep requests and new prescribers per congress.

    Congresses concentrate the small number of neuromuscular specialists who treat Duchenne.

    Risks and how to handle them

    • Promotional and medical mix

      Keep medical exchange with Medical Affairs.

    Evidence

    • Your websitePress releases: data on givinostat presented at the 2025 Neuromuscular Study Group meeting and the 2025 and 2026 MDA Clinical and Scientific Conferences, long-term data publications, the Phase 3 EPIDYS results in The Lancet Neurology, and the new U.S. headquarters in Concord, Massachusetts.Source
    • HiringDirector, Duvyzat HCP Marketing (posted October 14, 2026): owns "the HCP commercial strategy, omnichannel engagement, customer insights, congress strategy and agency leadership", will "Establish KPIs, dashboards and ROI measurement", lead "strategic congress planning, advisory boards" and "HCP product public relations", and "navigate all MLR requirements".Source
    • HiringAccess and thought leaders: a Field Reimbursement Manager (Texas, Missouri, Illinois, Michigan, Wisconsin, Minnesota) will "Partner with the sales team and patient hub/SP to identify both accounts that are experiencing reimbursement issues and specific patients that are not moving forward due to insurance delays"; a Thought Leader Liaison (East) is "the field-based arm of Marketing" for the "top 10-15 percent of KOLs".Source
    • HCP websiteduvyzathcp.com has a "REQUEST A REP" form "for US healthcare providers only", an NPI-based "Sign up for updates" form with consent to contact by email, text and phone, a video library, resources and a Patient Start Form.Source
  • 11

    The forecasting lead will run "patient funnel analysis" across specialty pharmacy, claims, EMR and CRM data, while both marketing directors must set KPIs and ROI. Without one shared funnel each team will report its own numbers.

    High impactHigh effort First result in 2 quarters Sr. Director

    First action

    Agree the six stage definitions.

    How to measure it

    Stages reported monthly

    Now
    –
    Target
    6 of 6
    By
    2 quarters

    Steps

    1. 1

      Define stages

      With all teams.

      Sr. Director, Integrated Performance Insights & Forecasting 2 weeks

    2. 2

      Map data

      Web, CRM, hub, SP.

      Sr. Manager, Field Reporting & Analytics 1 month

    3. 3

      Privacy review

      Aggregate only.

      Compliance 2 weeks

    4. 4

      Build the view

      Monthly dashboard.

      Sr. Manager, Field Reporting & Analytics 1 month

    5. 5

      Review

      Monthly with leaders.

      Sr. Director, Integrated Performance Insights & Forecasting monthly

    6. 6

      Act

      One fix per month.

      Duvyzat Brand Lead monthly

    First result
    2 quarters
    Cost
    Data engineering time
    Owner
    Sr. Director, Integrated Performance Insights & Forecasting

    Smallest test

    Report three stages this month.

    Why it works

    Define the stages (site visit, sign-up, HCP request, enrolment, first shipment, 6-month persistence), connect web, CRM and hub data at an aggregate level, and publish one monthly view by region and channel.

    Shared stages show where families and clinicians drop out, and where the next dollar should go.

    Risks and how to handle them

    • Data linking limits

      Stay aggregate and de-identified.

    Evidence

    • HiringSr. Director, Integrated Performance Insights & Forecasting (posted September 4, 2026): uses "specialty pharmacy, claims, EMR, CRM" data for "patient funnel analysis" and "therapy uptake patterns"; a Sr. Manager, Field Reporting & Analytics and a Chief of Staff are also open. The board lists 28 open roles.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
    • HiringDirector, Duvyzat HCP Marketing (posted October 14, 2026): owns "the HCP commercial strategy, omnichannel engagement, customer insights, congress strategy and agency leadership", will "Establish KPIs, dashboards and ROI measurement", lead "strategic congress planning, advisory boards" and "HCP product public relations", and "navigate all MLR requirements".Source
    • HiringAccess and thought leaders: a Field Reimbursement Manager (Texas, Missouri, Illinois, Michigan, Wisconsin, Minnesota) will "Partner with the sales team and patient hub/SP to identify both accounts that are experiencing reimbursement issues and specific patients that are not moving forward due to insurance delays"; a Thought Leader Liaison (East) is "the field-based arm of Marketing" for the "top 10-15 percent of KOLs".Source
  • 12

    ITF's corporate social presence is LinkedIn and a Facebook profile without a custom name, while the new Patient Marketing Director is expected to run social media and influencer programs. The "Real + Rare" stories are unbranded and made to be shared.

    Medium impactMedium effort First result in 1 quarter Director

    First action

    Write the moderation and adverse-event guide.

    How to measure it

    Monthly engaged followers

    Now
    –
    Target
    2,000
    By
    2 quarters

    Steps

    1. 1

      Guide

      Moderation and AE reporting.

      Pharmacovigilance 2 weeks

    2. 2

      Name the page

      Facebook custom name.

      Head of Corporate Communications 1 day

    3. 3

      Content plan

      Stories, sports, advocacy.

      Director, Duvyzat Patient Marketing 2 weeks

    4. 4

      Review

      MLR for the first month.

      Director, MLR Operations 2 weeks

    5. 5

      Launch

      Two posts a week.

      Director, Duvyzat Patient Marketing weekly

    6. 6

      Measure

      Engagement and site visits.

      Director, Duvyzat Patient Marketing monthly

    First result
    1 quarter
    Cost
    Agency and moderation time
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Post one Real + Rare clip on LinkedIn.

    Why it works

    Launch an unbranded Real + Rare channel (Instagram and Facebook) with short clips from the existing stories, adaptive sports content from the Volt Hockey sponsorship and advocacy news. Set comment moderation, adverse-event monitoring and a response guide before launch. Give the Facebook page a proper name.

    Families spend time on social, and unbranded stories build trust without product claims.

    Risks and how to handle them

    • Comments about the product

      Follow the AE guide and point to medical information.

    Evidence

    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
  • 13

    The Important Safety Information says the doctor will check blood counts and triglycerides before and during treatment, and ITF ARC offers in-home lab monitoring with a nurse. Families have to fit regular tests into busy lives.

    High impactMedium effort First result in 1 quarter Director

    First action

    Ask ARC which questions families ask most about monitoring.

    How to measure it

    Families using in-home monitoring

    Now
    –
    Target
    +20%
    By
    2 quarters

    Steps

    1. 1

      Collect questions

      From ARC.

      Patient services hub lead 1 week

    2. 2

      Draft

      Label wording only.

      Director, Duvyzat Patient Marketing 2 weeks

    3. 3

      Review

      MLR.

      Director, MLR Operations 2 weeks

    4. 4

      Spanish version

      With certified translation.

      Director, Duvyzat Patient Marketing 2 weeks

    5. 5

      Distribute

      Enrolment and emails.

      Patient services hub lead ongoing

    6. 6

      Measure

      Monitoring bookings.

      Sr. Director, Integrated Performance Insights & Forecasting monthly

    First result
    1 quarter
    Cost
    Design and review time
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Turn the monitoring flash card into an email.

    Why it works

    Create a simple companion (printable and email): what tests to expect, how to book in-home monitoring through ARC, and reminders before each test, using only approved label wording. Offer it at enrolment and through the on-treatment email series.

    Making the monitoring routine easier supports persistence, which the patient marketing role is measured on.

    Risks and how to handle them

    • Medical advice

      Always refer to the treating doctor.

    Evidence

    • Brand websiteduvyzat.com homepage: "The only nonsteroidal treatment indicated for Duchenne muscular dystrophy in people 6 years of age and older, regardless of their genetic variant or ability to walk." The Important Safety Information tells patients the doctor will check blood counts and triglyceride levels before and during treatment.Source
    • Brand websiteITF ARC page: insurance navigation, prior authorization and appeal support, home delivery, "Personalized pharmacist guidance", "Translation services available as needed", in-home lab monitoring with a registered nurse, a copay program ("as little as $0 per month" for eligible commercially insured patients), a Patient Assistance Program and temporary supply programs. English and Spanish ARC brochures are linked from this English page only.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
  • 14

    ITF funds disease awareness, quality of care, wellbeing and science, but applicants start with an email and a phone call, and the site shows only a few highlights such as Volt Hockey.

    Medium impactLow effort First result in 1 quarter Patient Advocacy lead

    First action

    Turn the eligibility rules into form questions.

    How to measure it

    Eligible proposals per cycle

    Now
    –
    Target
    +50%
    By
    2 quarters

    Steps

    1. 1

      Form

      Eligibility questions.

      Patient Advocacy lead 1 week

    2. 2

      Cycles

      Two a year.

      Patient Advocacy lead 1 day

    3. 3

      Review

      Compliance sign-off.

      Compliance 2 weeks

    4. 4

      Publish

      Form and funded list.

      Head of Corporate Communications 1 week

    5. 5

      Share

      With partners.

      Patient Advocacy lead 1 week

    6. 6

      Measure

      Proposals and quality.

      Patient Advocacy lead per cycle

    First result
    1 quarter
    Cost
    $0
    Owner
    Patient Advocacy lead

    Smallest test

    Publish last year's funded programs.

    Why it works

    Add an online application with eligibility questions (501(c)(3) status, other sponsors, dates), publish funding cycles, and list funded programs each year. Share the call for proposals with advocacy partners.

    A clear process brings more and better proposals, and a public list shows the community what ITF supports.

    Risks and how to handle them

    • Expectations of funding

      State selection rules clearly.

    Evidence

    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
  • 15

    The new Brand Insights & CI Director will run competitive intelligence. DUVYZAT's own wording is "The only nonsteroidal treatment indicated for Duchenne muscular dystrophy in people 6 years of age and older, regardless of their genetic variant or ability to walk"; rivals offer Spanish sites and different messages.

    Medium impactMedium effort First result in 1 quarter Director

    First action

    Capture the three rival sites this month.

    How to measure it

    KAMs using the brief

    Now
    –
    Target
    100%
    By
    2 quarters

    Steps

    1. 1

      Capture

      Public sites quarterly.

      Director, Brand Insights & Competitive Intelligence 1 week

    2. 2

      Compare

      Against approved messages.

      Director, Brand Insights & Competitive Intelligence 1 week

    3. 3

      Field input

      KAM and TLL questions.

      Thought Leader Liaison 1 week

    4. 4

      Brief

      One page.

      Director, Brand Insights & Competitive Intelligence 2 days

    5. 5

      Review

      Legal and medical.

      Director, MLR Operations 1 week

    6. 6

      Share

      Marketing and field.

      Head of Sales quarterly

    First result
    1 quarter
    Cost
    Staff time
    Owner
    Director, Brand Insights & Competitive Intelligence

    Smallest test

    Write the first one-page brief.

    Why it works

    Each quarter, capture rivals' public sites, HCP sites and congress presence, compare against DUVYZAT's approved messages, and give both marketing directors a one-page brief: gaps (such as Spanish), message overlaps and field questions.

    The field hears competitor claims daily; a short shared brief keeps responses consistent and compliant.

    Risks and how to handle them

    • Off-label discussions

      Keep to approved messages.

    Evidence

    • HiringA second therapeutic area: the Director, Brand Insights & Competitive Intelligence supports "a Phase III neurometabolic asset" through "patient journey development", "segmentation, positioning, messaging" and "launch readiness", and will "Direct intelligence-gathering activities at key scientific congresses"; ITF is also hiring a Global Medical Lead, a Field Medical Director and a Senior Director of Medical Affairs for its neurometabolic portfolio.Source
    • Brand websiteduvyzat.com homepage: "The only nonsteroidal treatment indicated for Duchenne muscular dystrophy in people 6 years of age and older, regardless of their genetic variant or ability to walk." The Important Safety Information tells patients the doctor will check blood counts and triglyceride levels before and during treatment.Source
    • Competitor researchRivals' own sites: AGAMREE (vamorolone), "an FDA-approved corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older", links a Spanish site at /es/; the ELEVIDYS site declares a Spanish ("es") version; EMFLAZA (deflazacort): "Help extend his now with EMFLAZA".Source

Big bets 3

Larger plays that can change the trajectory.

  • 16

    ITF has a steady stream of data (Lancet Neurology Phase 3 results, long-term publications, NMSG and MDA presentations) and writes community letters after each meeting. HCP marketing and patient marketing can each use the approved parts.

    High impactHigh effort First result in 1 quarter Sr. Director

    First action

    Map the next 12 months of publications and meetings.

    How to measure it

    Days from presentation to summary

    Now
    –
    Target
    <14
    By
    3 quarters

    Steps

    1. 1

      Plan

      Publication calendar.

      Sr. Director, Medical Affairs, Neuromuscular Team 1 month

    2. 2

      Templates

      HCP summary and letter.

      Director, Duvyzat HCP Marketing 2 weeks

    3. 3

      Pre-review

      MLR before the meeting.

      Director, MLR Operations per event

    4. 4

      Translate

      Spanish letters.

      Director, Duvyzat Patient Marketing per event

    5. 5

      Publish

      Sites and email.

      Head of Corporate Communications per event

    6. 6

      Measure

      Reads and rep requests.

      Sr. Manager, Field Reporting & Analytics quarterly

    First result
    1 quarter
    Cost
    Medical writing
    Owner
    Sr. Director, Medical Affairs, Neuromuscular Team

    Smallest test

    Prepare the next community letter template in advance.

    Why it works

    Plan publications and congress data a year ahead, prepare approved HCP summaries and community letters (in English and Spanish) for each, and update duvyzathcp.com and the Community Letters page the week the data is public.

    Specialists follow data; families follow the community letters. A planned rhythm keeps both informed.

    Risks and how to handle them

    • Promotional use of data

      Keep medical and promotional channels separate.

    Evidence

    • Your websitePress releases: data on givinostat presented at the 2025 Neuromuscular Study Group meeting and the 2025 and 2026 MDA Clinical and Scientific Conferences, long-term data publications, the Phase 3 EPIDYS results in The Lancet Neurology, and the new U.S. headquarters in Concord, Massachusetts.Source
    • Your websiteCommunity Letters: six letters from March 2024 to March 2026, each with a Spanish version (the Spanish versions were added on September 10, 2026), and a Spanish press release on U.S. commercial availability.Source
    • HiringDirector, Duvyzat HCP Marketing (posted October 14, 2026): owns "the HCP commercial strategy, omnichannel engagement, customer insights, congress strategy and agency leadership", will "Establish KPIs, dashboards and ROI measurement", lead "strategic congress planning, advisory boards" and "HCP product public relations", and "navigate all MLR requirements".Source
    • HiringA second therapeutic area: the Director, Brand Insights & Competitive Intelligence supports "a Phase III neurometabolic asset" through "patient journey development", "segmentation, positioning, messaging" and "launch readiness", and will "Direct intelligence-gathering activities at key scientific congresses"; ITF is also hiring a Global Medical Lead, a Field Medical Director and a Senior Director of Medical Affairs for its neurometabolic portfolio.Source
  • 17

    ITF is building a team for a Phase III neurometabolic asset (insights, global medical, field medical and medical affairs), while its corporate site, pipeline and Areas of Focus describe Duchenne only and the pipeline page says ITF is seeking partners.

    High impactHigh effort First result in 2 quarters Chief of Staff

    First action

    Agree what the company will disclose and when.

    How to measure it

    Launch-readiness checklist complete

    Now
    –
    Target
    80%
    By
    4 quarters

    Steps

    1. 1

      Disclosure plan

      What and when.

      Chief of Staff 1 month

    2. 2

      Corporate story

      Multi-area narrative.

      Head of Corporate Communications 1 quarter

    3. 3

      Advocacy mapping

      Groups in the new area.

      Patient Advocacy lead 1 quarter

    4. 4

      Insights

      Patient journey research.

      Director, Brand Insights & Competitive Intelligence 2 quarters

    5. 5

      MLR capacity

      Plan reviewer load.

      Director, MLR Operations 1 quarter

    6. 6

      Review

      Quarterly with leaders.

      Chief of Staff quarterly

    First result
    2 quarters
    Cost
    Staff time
    Owner
    Chief of Staff

    Smallest test

    Write the one-page disclosure plan.

    Why it works

    Plan the corporate story for a multi-area company: when the company chooses to disclose, list the program on the pipeline page with its phase, add an Areas of Focus section with disease education, build advocacy relationships early through Patient Advocacy and Medical Affairs, and reuse the DMD playbook (insights, MLR capacity, ARC-style support design). No product promotion or patient targeting before approval.

    Rare-disease communities judge companies by how they show up before launch; the DMD record is ITF's best proof.

    Risks and how to handle them

    • Pre-approval promotion

      Corporate and medical content only, reviewed by Legal.

    Evidence

    • HiringA second therapeutic area: the Director, Brand Insights & Competitive Intelligence supports "a Phase III neurometabolic asset" through "patient journey development", "segmentation, positioning, messaging" and "launch readiness", and will "Direct intelligence-gathering activities at key scientific congresses"; ITF is also hiring a Global Medical Lead, a Field Medical Director and a Senior Director of Medical Affairs for its neurometabolic portfolio.Source
    • Your websitePipeline page: givinostat is approved for Duchenne muscular dystrophy, in Phase 1/2 for Becker muscular dystrophy and in Phase 3 for polycythemia vera; ITF is "actively seeking partners with high-quality assets". Areas of Focus covers Duchenne only, describes it as "a rare neuromuscular disorder characterized by progressive muscle weakness and damage", and cites a study on "Delayed diagnosis in Duchenne muscular dystrophy".Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
    • HiringDirector, Medical, Legal, & Regulatory (MLR) Operations (posted October 2, 2026): owns the review model "end-to-end", is business owner for "Veeva Vault PromoMats", plans "reviewer capacity" for "new product launches, indications, label changes", and tracks "submission volume, cycle time, SLA adherence, review rounds".Source
  • 18

    ITF's Areas of Focus page cites research on delayed diagnosis in Duchenne, its sponsorships fund disease awareness and education, and the patient marketing role covers non-branded media. Earlier diagnosis helps families reach specialists and every available option sooner.

    High impactHigh effort First result in 2 quarters Director

    First action

    Agree goals with two advocacy partners.

    How to measure it

    Referrals tracked by partners

    Now
    –
    Target
    Baseline, then +20%
    By
    4 quarters

    Steps

    1. 1

      Partners

      Two advocacy groups.

      Patient Advocacy lead 1 month

    2. 2

      Content

      Unbranded education.

      Director, Duvyzat Patient Marketing 1 quarter

    3. 3

      Medical review

      Accuracy.

      Sr. Director, Medical Affairs, Neuromuscular Team 1 month

    4. 4

      Pediatrician outreach

      Through partners.

      Patient Advocacy lead 1 quarter

    5. 5

      Media

      Unbranded digital.

      Director, Duvyzat Patient Marketing 2 quarters

    6. 6

      Measure

      Partner referrals.

      Sr. Director, Integrated Performance Insights & Forecasting quarterly

    First result
    2 quarters
    Cost
    Program budget
    Owner
    Director, Duvyzat Patient Marketing

    Smallest test

    Fund one partner's pediatrician education piece.

    Why it works

    Co-fund an unbranded awareness program with advocacy partners: early signs of Duchenne for parents and pediatricians, the first steps to a diagnosis as set out by medical experts, and where to find a neuromuscular center. Keep it non-promotional and measure referrals to centers.

    The research ITF cites shows diagnosis is often delayed; shortening that path is good for children and builds trust in ITF.

    Risks and how to handle them

    • Seen as promotion

      Keep it unbranded and partner-led.

    Evidence

    • Your websitePipeline page: givinostat is approved for Duchenne muscular dystrophy, in Phase 1/2 for Becker muscular dystrophy and in Phase 3 for polycythemia vera; ITF is "actively seeking partners with high-quality assets". Areas of Focus covers Duchenne only, describes it as "a rare neuromuscular disorder characterized by progressive muscle weakness and damage", and cites a study on "Delayed diagnosis in Duchenne muscular dystrophy".Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
    • HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source
    • HiringField build-out: a Head of Sales (posted August 24, 2026) to lead "Regional Business Directors and Key Account Managers" for "DUVYZAT (givinostat), the first nonsteroidal therapy approved for all genetic variants of Duchenne muscular dystrophy", set objectives for "patient starts, patient adherence", and build relationships with "neuromuscular centers, MDA care centers, academic and pediatric institutions"; seven Key Account Manager posts (Boston, Detroit, Miami, Minneapolis, New York City, Philadelphia, San Antonio) and a Regional Business Director, Central.Source

Wildcards 3

Unexpected experiments, each with a cheap way to test it.

  • 19

    ITF has 28 open roles across sales, medical, marketing and analytics, and its careers pages talk about community and purpose. Rare-disease candidates choose companies for their patient focus.

    Medium impactLow effort First result in 1 quarter Director

    First action

    Record two employee clips at the next community event.

    How to measure it

    Median days to fill

    Now
    –
    Target
    -15%
    By
    2 quarters

    Steps

    1. 1

      Plan

      Clips and quotes.

      Director, Talent Management & Development 1 week

    2. 2

      Record

      At events.

      Head of Corporate Communications 1 month

    3. 3

      Publish

      Careers and posts.

      Director, Talent Management & Development 1 week

    4. 4

      Share

      LinkedIn.

      Head of Corporate Communications weekly

    5. 5

      Ask hires

      Source survey.

      Director, Talent Management & Development ongoing

    6. 6

      Measure

      Applicants per role.

      Director, Talent Management & Development monthly

    First result
    1 quarter
    Cost
    Video time
    Owner
    Director, Talent Management & Development

    Smallest test

    Add one clip to the careers page.

    Why it works

    Add short employee and community clips (Volt Hockey, advocacy events, Real + Rare) to the careers pages and Greenhouse posts, and ask hires why they joined.

    Purpose-led content attracts experienced rare-disease talent faster, which shortens time to fill field territories.

    Risks and how to handle them

    • Patient privacy

      Only families who agreed to share.

    Evidence

    • HiringSr. Director, Integrated Performance Insights & Forecasting (posted September 4, 2026): uses "specialty pharmacy, claims, EMR, CRM" data for "patient funnel analysis" and "therapy uptake patterns"; a Sr. Manager, Field Reporting & Analytics and a Chief of Staff are also open. The board lists 28 open roles.Source
    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
    • Your websiteSponsorships: funding for "Disease Awareness and Education", "Quality of Care", "Social and Emotional Wellbeing" and "Medical and Scientific Advancement"; applicants start by email, then a call, then an application; highlights include the US Volt Hockey Summer Training Camp. Patient Advocacy lists partners such as MDA, Parent Project Muscular Dystrophy, CureDuchenne, Jett Foundation, Little Hercules Foundation, Team Joseph and NORD.Source
  • 20

    KAMs are asked to report "prescriber opinion and competitive activity", TLLs to "Gather and communicate actionable market insights", and the CI Director to integrate it all. Insights often stay in CRM notes.

    Medium impactLow effort First result in 1 month Director

    First action

    Add the three CRM fields.

    How to measure it

    Field entries per month

    Now
    –
    Target
    100
    By
    1 quarter

    Steps

    1. 1

      Fields

      Three structured fields.

      Sr. Manager, Field Reporting & Analytics 1 week

    2. 2

      Train

      Field teams.

      Head of Sales 1 day

    3. 3

      Summarise

      Monthly note.

      Director, Brand Insights & Competitive Intelligence monthly

    4. 4

      Share

      Marketing and medical.

      Director, Brand Insights & Competitive Intelligence monthly

    5. 5

      Act

      One change per month.

      Duvyzat Brand Lead monthly

    6. 6

      Feedback

      Tell the field.

      Head of Sales monthly

    First result
    1 month
    Cost
    Staff time
    Owner
    Director, Brand Insights & Competitive Intelligence

    Smallest test

    Collect one month of fields.

    Why it works

    Add three structured CRM fields (top question, objection, competitor mention), summarise them monthly in a one-page note, and close the loop by telling the field what changed because of it.

    Structured field input is the cheapest market research a rare-disease brand has.

    Risks and how to handle them

    • Off-label content in notes

      Train on compliant capture.

    Evidence

    • HiringField build-out: a Head of Sales (posted August 24, 2026) to lead "Regional Business Directors and Key Account Managers" for "DUVYZAT (givinostat), the first nonsteroidal therapy approved for all genetic variants of Duchenne muscular dystrophy", set objectives for "patient starts, patient adherence", and build relationships with "neuromuscular centers, MDA care centers, academic and pediatric institutions"; seven Key Account Manager posts (Boston, Detroit, Miami, Minneapolis, New York City, Philadelphia, San Antonio) and a Regional Business Director, Central.Source
    • HiringAccess and thought leaders: a Field Reimbursement Manager (Texas, Missouri, Illinois, Michigan, Wisconsin, Minnesota) will "Partner with the sales team and patient hub/SP to identify both accounts that are experiencing reimbursement issues and specific patients that are not moving forward due to insurance delays"; a Thought Leader Liaison (East) is "the field-based arm of Marketing" for the "top 10-15 percent of KOLs".Source
    • HiringA second therapeutic area: the Director, Brand Insights & Competitive Intelligence supports "a Phase III neurometabolic asset" through "patient journey development", "segmentation, positioning, messaging" and "launch readiness", and will "Direct intelligence-gathering activities at key scientific congresses"; ITF is also hiring a Global Medical Lead, a Field Medical Director and a Senior Director of Medical Affairs for its neurometabolic portfolio.Source
  • 21

    Lighthouse flags low contrast and small touch targets on itftherapeutics.com, and ITF's own stories feature people who use power wheelchairs and adapted sports. Duchenne causes progressive muscle weakness, so many visitors may rely on adapted devices, voice control or switch access.

    Medium impactLow effort First result in 1 month Web agency

    First action

    Run an accessibility check on the three main tasks.

    How to measure it

    Lighthouse accessibility score

    Now
    –
    Target
    100
    By
    1 month

    Steps

    1. 1

      Audit

      Both sites.

      Web agency 1 week

    2. 2

      Fix contrast

      Theme colours.

      Web agency 2 days

    3. 3

      Fix targets

      Buttons and links.

      Web agency 2 days

    4. 4

      User test

      With a family.

      Director, Duvyzat Patient Marketing 2 weeks

    5. 5

      Statement

      Publish.

      Head of Corporate Communications 1 day

    6. 6

      Recheck

      Each release.

      Web agency per release

    First result
    1 month
    Cost
    Agency hours
    Owner
    Web agency

    Smallest test

    Fix the contrast on the homepage.

    Why it works

    Fix contrast and touch targets, test both sites with screen readers and switch access, ask an ambassador family to review the key tasks (sign up, find ARC, register for an event), and publish an accessibility statement.

    The people the sites are for should be able to use them easily; it is also the right signal for a patient-centric company.

    Risks and how to handle them

    • Design changes need review

      Visual-only changes logged with MLR.

    Evidence

    • Google PageSpeeditftherapeutics.com homepage: Lighthouse mobile performance 73 (desktop 89) with a lab Largest Contentful Paint of 6.4 seconds on mobile, but real Chrome visitors pass Core Web Vitals (LCP 1.7 seconds at the 75th percentile, INP 49 ms, CLS 0). SEO 85 ("Document does not have a meta description", "Links do not have descriptive text"); accessibility 92 with low colour contrast and small touch targets flagged.Source
    • Your websiteCorporate site: "Real + Rare" stories ("See the Life. Not the Label.") of three people with Duchenne, the latest added September 1, 2026; the homepage and other pages checked have no meta description; social links are LinkedIn and a Facebook profile without a custom name; the blog has seven posts, including "FDA Approval Granted, Access Denied - Now What?" by the Head of Value & Access, and its index shows no posts in plain HTML.Source
    • Your websitePipeline page: givinostat is approved for Duchenne muscular dystrophy, in Phase 1/2 for Becker muscular dystrophy and in Phase 3 for polycythemia vera; ITF is "actively seeking partners with high-quality assets". Areas of Focus covers Duchenne only, describes it as "a rare neuromuscular disorder characterized by progressive muscle weakness and damage", and cites a study on "Delayed diagnosis in Duchenne muscular dystrophy".Source
More example playbooks and reviews

More growth playbooks

Other companies we have researched, each read from what they are hiring for.

  • Figma growth strategyA collaborative design and product platform: Figma Design, Dev Mode, Figma Make (prompt to code), FigJam, Slides, Draw, Sites, Buzz…22 growth ideas
  • Articuler growth strategyAn AI professional networking platform that matches people by intent across 980M+ public profiles, curated directories and event lists…21 growth ideas
  • Modal growth strategyServerless cloud infrastructure for AI: inference, training and RL, sandboxes for coding agents and untrusted code, and batch jobs, with…21 growth ideas
  • Nscale growth strategyA full-stack AI cloud: power, data centers, GPU compute, managed Kubernetes and Slurm, serverless and dedicated inference, built in Europe…22 growth ideas
  • BootLoop growth strategyAn AI firmware agent (BootLoop Develop) and a hardware-in-the-loop testing framework (BootLoop Test). It reads schematics and datasheets…23 growth ideas
  • Modern Health growth strategyA global workforce mental health platform: coaching, therapy, psychiatry, Pathways programs, Circles community sessions, family and…21 growth ideas
  • Maze growth strategyA user and market research platform: participant recruitment from its own panel, unmoderated tests, surveys, moderated and AI-moderated…21 growth ideas
  • Work4Flow growth strategyA ServiceNow Premier Partner focused on AI readiness: advisory, Now Assist and agentic AI implementations, and more than 20 ServiceNow…23 growth ideas

See every playbook and website review

Independent research. Programmable wrote this playbook from public sources, as they stood on October 26, 2026, and cites them throughout. ITF Therapeutics did not commission, review or endorse it, and Programmable is not affiliated with ITF Therapeutics. Company and product names are trademarks of their owners, used only to identify them. The ideas are suggestions and opinion, not professional, legal or financial advice, and not statements about how ITF Therapeutics runs its business.

Something wrong, or do you represent ITF Therapeutics? Email [email protected] and we will correct it or take it down.

30/60/90 roadmap

What to focus on in each month, and the ideas that carry it.

  1. Days 1 to 307 ideas

    Spanish path, sitemap, meta descriptions, on-treatment journey, claims library and visible event dates; accessibility fixes.

  2. Days 31 to 6011 ideas

    Rep routing, access-stall alerts, ambassadors, congress plan, shared funnel, unbranded social, monitoring companion, sponsorships and competitor brief; recruiting content and field insights.

  3. Days 61 to 903 ideas

    Commit to the evidence program, second-area readiness and diagnosis awareness.

The research behind the plan

3 research areas, each summarised in a few lines. Open any of them for the full detail.

Customers

What customers say

Customers value A nonsteroidal option for all genetic variants. The most cited problem: insurance delays and prior authorization.

  • Help with insurance and costs through ITF ARC
  • Regular blood tests
  • In their words: “Duchenne”

Market

Competitive landscape

3 competitors compared: AGAMREE (vamorolone), ELEVIDYS and EMFLAZA (deflazacort).

  • Gap to exploit: Complete Spanish-language support journeys
  • AGAMREE (vamorolone): A corticosteroid, where DUVYZAT is nonsteroidal
  • ELEVIDYS: A different treatment approach from an oral medicine

Hiring signals

ITF is building the second phase of its DUVYZAT launch and a second therapeutic area at once.

  • Director, Duvyzat Patient Marketing: Ambassadors, social, adoption and persistence. Ideas 1, 4, 9, 12, 13.
  • Director, Duvyzat HCP Marketing: Omnichannel, congresses and KPIs. Ideas 7, 10.
  • Head of Sales: National field team for patient starts and adherence. Ideas 7, 20.

From the team that wrote this playbook

All products
  • ProgrammableAgencyWorking AI systems in days, not quarters (opens programmable.agency in a new tab)
  • ProgrammableInfoAn agent that finds, researches and asks firstNew accounts get 100,000 free enrichment credits with code BETA100K (opens programmable.info in a new tab)
  • ProgrammableDigitalScreenshots in, an animated product demo out (opens programmable.digital in a new tab)
  • ProgrammableWatchKnow the day a supplier falls out of compliance (opens programmable.watch in a new tab)
  • ProgrammableTalkGet registrants for your events, and know who’s coming (opens programmable.talk in a new tab)
  • ProgrammableMediaAn AI note taker, interpreter and webinar host for your calls (opens programmable.media in a new tab)
  • ProgrammablePageText what you need, your customer gets a page that works (opens programmable.page in a new tab)
  • ProgrammableCommunityForums with labelled AI members, never empty (opens programmable.community in a new tab)
ProgrammableMarketing
ExamplesLeaderboardsProductsTermsPrivacyCookiesDPALegalContact

© 2026 AI-Powered Growth Intelligence